Skip to content
Main Navigation
About us
Company profile
Our values
Our strategy
Board of Directors
Senior management
Our history
Research and development
Technology platform
Therapeutic areas
Pipeline
Scientific papers and presentations
Partnering
Our approach
Our partnerships
Investors
Financial reports and presentations
Share information
Analyst coverage
Major shareholders
Financial calendar
Corporate governance
Corporate governance statements
Dividend policy
Annual general meeting
Articles of association
Safe harbour statement
Whistleblower policy
Risk management
Investor relations policy
ESG
Email alerts
Media
News and announcements
Image library
Glossary
Email alerts
Careers
Life at Nykode
Meet us
Open positions
Search
Media
News and Announcements
Newest first
Oldest first
Announcements
News
Search
Reset
18/04/2023
Nykode Therapeutics announces positive final results from its Phase 2 trial of VB10.16 in combination with PD-L1 inhibitor atezolizumab in advanced cervical cancer
22/02/2023
Nykode Therapeutics to announce financial results for the fourth quarter 2022 and host webcast presentation on February 28, 2023
10/02/2023
Nykode Therapeutics Announces Collaboration with The GOG Foundation, Inc. to Conduct the VB-C-04 Trial in Advanced Cervical Cancer
07/02/2023
Nykode Therapeutics to Present at SVB Securities Global Biopharma Conference
27/12/2022
Nykode Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
Pages:
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
Load more
Sorry, nothing found in this query
Privacy statement
Cookie policy
Disclaimer